Acorda Therapeutics Receives Silver Awards From Medical Marketing & Media Magazine For Consumer Website And AMPYRA Healthcare Professional Print Campaign

Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that the Company received two Silver Awards at the annual Medical Marketing & Media (MM&M) Awards ceremony: one for its Consumer site in the category of Best Branded Website, and a second for its AMPYRA healthcare professional campaign in the Best Professional Print Campaign category. The MM&M Awards recognize exceptional creativity and marketing effectiveness among all companies in the pharmaceutical and biotechnology industries. There are 24 categories of awards and only a Gold and Silver Award are presented for each category. This year was especially competitive with two comprehensive rounds of scoring by more than 100 independent industry judges, representing a wide variety of backgrounds in healthcare.

“It is an honor to have been recognized by our peers in the industry for our innovative consumer and health care professional communications,” said Lauren Sabella, Acorda’s Executive Vice President, Commercial Development. “These awards are a testament to the passion and commitment of Acorda’s employees to making a positive difference in the lives of people with MS. Our goal is to increase awareness of important information about MS and AMPYRA, helping to facilitate educated dialogue between physicians and consumers about their healthcare decisions.”

In addition to being recognized by MM&M, in 2012 Acorda has also been awarded the PM360 Trailblazer Award for best health care professional advertising campaign, as well as Gold and Silver W3 Awards from the International Academy of the Visual Arts for The Company also received two Telly Awards this year for online video production and editing.

AMPYRA is approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with MS. This was demonstrated by an improvement in walking speed.

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Stiff-Arms Investor's Demand for Sale

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe